Neurocrine Biosciences, Inc.

Neurocrine Biosciences, Inc. is an American biopharmaceutical company dedicated to discovering, developing, and commercializing innovative treatments for patients suffering from under-addressed neurological, endocrine, psychiatric, and immunological disorders. Founded in 1992, the company's mission is to relieve suffering for individuals with significant unmet medical needs through scientific excellence and patient-centric drug development. Its corporate headquarters are located in San Diego, California.

The company's diverse portfolio includes several FDA-approved medicines. Key products include INGREZZA (valbenazine) for tardive dyskinesia and chorea associated with Huntington's disease, and CRENESSITY (crinecerfont) for classic congenital adrenal hyperplasia (CAH). Additionally, through a collaboration with AbbVie, Neurocrine Biosciences receives royalties from products like ORILISSA (elagolix) for endometriosis and ORIAHNN (elagolix, estradiol, and norethindrone acetate capsules) for uterine fibroids. The company recently expanded its portfolio with the acquisition of VYKAT XR for Prader-Willi Syndrome.

Recent notable developments include the acquisition of Soleno Therapeutics for approximately $2.8 billion, which added VYKAT XR to its commercial offerings, further strengthening its endocrinology and rare disease pipeline. Neurocrine Biosciences also presented new two-year data for CRENESSITY in classic congenital adrenal hyperplasia, demonstrating durable hormone control and reduced glucocorticoid exposure in both pediatric and adult patients. Kyle W. Gano, Ph.D., serves as the President and Chief Executive Officer, having been appointed in October 2024. The company maintains a robust pipeline of drug candidates in various stages of clinical development, focusing on expanding indications for existing drugs and pioneering new treatments across its therapeutic areas.